FindTrial
Sign In

Use of magnetic tracer for sentinel lymph node biopsy in breast cancer is non inferior to the standard dual tracers technique: A multi-center non-inferior randomized trial

Use of magnetic tracer for sentinel lymph node biopsy in breast cancer is non inferior to the standard dual tracers technique: A multi-center non-inferior randomized trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038120
Enrollment
Unknown
Registered
2020-09-11
Start date
2020-11-02
Completion date
Unknown
Last updated
2020-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

A:Magnetic tracer
B:Dual tracer

Sponsors

North District Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patient with breast cancer scheduled to have SLNB and who are clinically and radiologically node negative

Exclusion criteria

Exclusion criteria: Patient treated with neoadjuvant chemotherapy, history of axillary radiation, history of ipsilateral axillary surgery; non palpable breast cancer requiring simultaneous localization; patient with known intolerance or hypersensitivity to iron or dextran compounds, magnetic tracers or SPIO; with an iron-overload disease; with pacemakers or other implantable devices on the chest wall; with known hypersensitivity to blue dye; who could not or did not receive radioisotope

Design outcomes

Primary

MeasureTime frame
Identification rate of SLN;—

Countries

China

Contacts

Public ContactHUNG KA WAI RAY

North District Hospital

hkw879@ha.org.hk+852 91616765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026